Klinik Araştırma
BibTex RIS Kaynak Göster

COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?

Yıl 2021, Cilt: 5 Sayı: 3, 279 - 284, 30.12.2021
https://doi.org/10.25048/tudod.959022

Öz

Aim: This study aims to analyze the effect of diabetes and diabetes drugs on the outcome of COVID-19 patients.
Material and Methods: All the patients with diabetes hospitalized for COVID-19 between March 15, 2020 and June 15, 2020 at Istanbul
University Faculty of Medicine were screened. Outcomes of the patients were compared with patients without diabetes.
Results: Among six hundred fourteen patients (59.8% male, n=367) there were 151 patients with diabetes (24.5%). Patients with
diabetes were hospitalized longer than patients without (12.1±10.3 vs. 10.2±7.3, p=0.037 in days), had higher intensive care unit (ICU)
hospitalization rate (20.5% (n=31) vs. 12.0% (n=56), p=0.016, OR:1.8 (1.1-2.9)) and mortality rate (15.8% (n=24) vs. 7.7% (n=36,
p=0.007), OR:2.1(1.2-3.8)).
There was no difference in admission to ICU between patients who use metformin, basal insulin or bolus insulin regarding admission
to ICU compared to patients who don’t (p= 0.32, p=0.22 and p=0.64, respectively). No patient on sodium-glucose co-transporter-2
treatment was treated in ICU. Death rate didn’t differ between patients regarding their treatment modalities.
Conclusion: Patients with diabetes had worse outcomes than non-diabetic patients, and according to our findings and no anti-diabetic
drug has a beneficial or harmful effect.

Proje Numarası

Çalışmaya ilişkin Sağlık Bakanlığı onayı 19.05.2020 tarihinde 2020-05-14T12_59_48 numaralı onay numarası ile alınmıştır. 21.05.2020 tarihinde de İstanbul Tıp Fakültesi Etik Kurulu'ndan onay alınmıştır.

Kaynakça

  • Reference1 Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. The Lancet Global Health 2020.8(4): e480, Doi: 10.1016/S2214-109X(20)30068-1.
  • Reference2 Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. Journal of Internal Medicine, 2020 Oct;288(4):469-476. Doi: 10.1111/joim.13119.
  • Reference3 Poblador-Plou B, Carmona-Pírez J, Ioakeim-Skoufa I, Poncel-Falcó A, Bliek-Bueno K et al. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: Results from the PRECOVID study in Spain. International Journal of Environmental Research and Public Health, 2020;17(14):5171. Doi: 10.3390/ijerph17145171.
  • Reference4 Zhou F, Yu T, Du R, Fan G, Liu Y. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 28;395(10229):1054-1062. Doi: 10.1016/S0140-6736(20)30566-3.
  • Reference5 Guo W, Li M, Dong Y, Zhou H, Zhang Z. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metabolism Research and Reviews 2020; e3319. Doi: 10.1002/dmrr.3319.
  • Reference6 Guo L, Shi Z, Zhang Y, Wang C, Do Vale Moreira NC, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Research and Clinical Practice 2020; 166:108346. Doi: 10.1016/j.diabres.2020.108346.
  • Reference7 Cheng X, Liu YM, Li H, Zhang X, Lei, F et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism 2020; 32(4):537-547. Doi: 10.1016/j.cmet.2020.08.013.
  • Reference8 Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Research and Clinical Practice 2020; 164:108183. Doi: 10.1016/j.diabres.2020.108183.
  • Reference9 Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R et al. Clinical Characteristics of Covid-19 in New York City. New England Journal of Medicine 2020; 382(24):2372-2374. Doi: 10.1056/nejmc2010419.
  • Reference10 Bode B, Garrett V, Messler J, McFarland R, Crowe J. et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology 2020; 14(4):813-821. Doi: 10.1177/1932296820924469.
  • Reference11 Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, et al. Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. Journal of Endocrinological Investigation 2020; 1-8. Doi: 10.1007/s40618-020-01382-7.
  • Reference12 Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases 2020; 30(8):1236-1248. Doi: 10.1016/j.numecd.2020.05.014.
  • Reference13 Holman N, Knighton P, Kar P, O’Keefe J, Curley M et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes and Endocrinology 2020; 8(10):823-833. Doi: 10.1016/S2213-8587(20)30271-0.
  • Reference14 Chen Y, Yang D, Cheng B, Chen J, Peng A et al. Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication. Diabetes Care 2020; 43(7):1399-1407.Doi: 10.2337/dc20-0660.
  • Reference15 Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. European Heart Journal - Cardiovascular Pharmacotherapy 2020; Doi: 10.1093/ehjcvp/pvaa098.
  • Reference16 Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metabolism 2021.33(1): 65-77.e2, Doi: 10.1016/j.cmet.2020.11.014.
  • Reference17 Riahi S, Sombra LRS, Lo KB, Chacko SR, Neto AGM et al. Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19. Endocrine Research 2020; 00(00): 1–6, Doi: 10.1080/07435800.2020.1856865.
  • Reference18 Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica 2020; 57(7): 779–783, Doi: 10.1007/s00592-020-01539-z.
  • Reference19 Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R et al. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice 2021; 171: 108444, Doi: 10.1016/j.diabres.2020.108444.

Covid-19 ve Diyabet: Antidiyabetik İlaçlar ile Sonlanımlarda Fark Var mı?

Yıl 2021, Cilt: 5 Sayı: 3, 279 - 284, 30.12.2021
https://doi.org/10.25048/tudod.959022

Öz

Amaç: Bu çalışma, diyabet ve diyabet ilaçlarının COVID-19 hastalarının sonuçları üzerindeki etkisini analiz etmeyi amaçlamaktadır.
Gereç ve Yöntemler: 15 Mart 2020-15 Haziran 2020 tarihleri arasında İstanbul Üniversitesi İstanbul Tıp Fakültesi'nde COVID-19
nedeniyle hastaneye yatırılan tüm diyabet hastaları tarandı. Hastaların sonuçları diyabeti olmayan hastalarla karşılaştırıldı.
Bulgular: Altı yüz ondört hastanın (%59,8 erkek, n=367) 151 tanesi diyabet hastası (%24,5) idi. Diyabetli hastalar diyabeti olmayan
hastalardan daha uzun süre hastanede yattı (12,1±10,3'e karşı 10,2±7,3 /gün p=0,037), diyabetlilerin yoğun bakım ünitesinde (YBÜ)
yatış oranı (20,5% (n=31) ve 12,0% (n) =56), p=0,016, OR:1,8 (1,1-2,9)) ve ölüm oranları (%15,8 (n=24) ve %7,7 (n=36, p=0,007),
OR:2,1(1,2-3,8)) daha yüksekti.
Metformin, bazal insülin veya bolus insülin kullanan hastaların YBÜ’e yatışı açısından kullanmayanlara göre fark yoktu (sırasıyla p=0,32,
p=0,22 ve p=0,64). Sodyum-glukoz kotransporter-2 tedavisi alan hiçbir hasta YBÜ'de tedavi edilmedi. Diyabet hastalarının ölüm oranı,
aldıkları tedavi yöntemlerine göre hastalar arasında farklılık göstermedi.
Sonuç: Diyabetli hastalar diyabetik olmayan hastalara göre daha kötü sonuçlara sahipti ve bizim bulgularımıza göre hiçbir antidiyabetik
ilacın yararlı veya zararlı etkisi yoktu.

Proje Numarası

Çalışmaya ilişkin Sağlık Bakanlığı onayı 19.05.2020 tarihinde 2020-05-14T12_59_48 numaralı onay numarası ile alınmıştır. 21.05.2020 tarihinde de İstanbul Tıp Fakültesi Etik Kurulu'ndan onay alınmıştır.

Kaynakça

  • Reference1 Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. The Lancet Global Health 2020.8(4): e480, Doi: 10.1016/S2214-109X(20)30068-1.
  • Reference2 Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. Journal of Internal Medicine, 2020 Oct;288(4):469-476. Doi: 10.1111/joim.13119.
  • Reference3 Poblador-Plou B, Carmona-Pírez J, Ioakeim-Skoufa I, Poncel-Falcó A, Bliek-Bueno K et al. Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: Results from the PRECOVID study in Spain. International Journal of Environmental Research and Public Health, 2020;17(14):5171. Doi: 10.3390/ijerph17145171.
  • Reference4 Zhou F, Yu T, Du R, Fan G, Liu Y. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 28;395(10229):1054-1062. Doi: 10.1016/S0140-6736(20)30566-3.
  • Reference5 Guo W, Li M, Dong Y, Zhou H, Zhang Z. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/Metabolism Research and Reviews 2020; e3319. Doi: 10.1002/dmrr.3319.
  • Reference6 Guo L, Shi Z, Zhang Y, Wang C, Do Vale Moreira NC, et al. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Research and Clinical Practice 2020; 166:108346. Doi: 10.1016/j.diabres.2020.108346.
  • Reference7 Cheng X, Liu YM, Li H, Zhang X, Lei, F et al. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism 2020; 32(4):537-547. Doi: 10.1016/j.cmet.2020.08.013.
  • Reference8 Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Research and Clinical Practice 2020; 164:108183. Doi: 10.1016/j.diabres.2020.108183.
  • Reference9 Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R et al. Clinical Characteristics of Covid-19 in New York City. New England Journal of Medicine 2020; 382(24):2372-2374. Doi: 10.1056/nejmc2010419.
  • Reference10 Bode B, Garrett V, Messler J, McFarland R, Crowe J. et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology 2020; 14(4):813-821. Doi: 10.1177/1932296820924469.
  • Reference11 Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, et al. Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. Journal of Endocrinological Investigation 2020; 1-8. Doi: 10.1007/s40618-020-01382-7.
  • Reference12 Mantovani A, Byrne CD, Zheng MH, Targher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutrition, Metabolism and Cardiovascular Diseases 2020; 30(8):1236-1248. Doi: 10.1016/j.numecd.2020.05.014.
  • Reference13 Holman N, Knighton P, Kar P, O’Keefe J, Curley M et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. The Lancet Diabetes and Endocrinology 2020; 8(10):823-833. Doi: 10.1016/S2213-8587(20)30271-0.
  • Reference14 Chen Y, Yang D, Cheng B, Chen J, Peng A et al. Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication. Diabetes Care 2020; 43(7):1399-1407.Doi: 10.2337/dc20-0660.
  • Reference15 Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. European Heart Journal - Cardiovascular Pharmacotherapy 2020; Doi: 10.1093/ehjcvp/pvaa098.
  • Reference16 Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metabolism 2021.33(1): 65-77.e2, Doi: 10.1016/j.cmet.2020.11.014.
  • Reference17 Riahi S, Sombra LRS, Lo KB, Chacko SR, Neto AGM et al. Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19. Endocrine Research 2020; 00(00): 1–6, Doi: 10.1080/07435800.2020.1856865.
  • Reference18 Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica 2020; 57(7): 779–783, Doi: 10.1007/s00592-020-01539-z.
  • Reference19 Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R et al. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice 2021; 171: 108444, Doi: 10.1016/j.diabres.2020.108444.
Toplam 19 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makalesi
Yazarlar

Ramazan Çakmak 0000-0003-3815-7444

Özge Telci Çaklılı 0000-0001-7566-5427

Ayşe Ok Bu kişi benim 0000-0002-1074-1801

Ümmü Mutlu 0000-0002-5259-7326

Göktuğ Sarıbeyliler Bu kişi benim 0000-0002-6365-4621

Vefa Seferova Nasifova Bu kişi benim 0000-0002-1263-791X

Alpay Medetalibeyoğlu 0000-0002-1074-1801

Naci Şenkal 0000-0001-7072-8724

Yunus Çatma Bu kişi benim 0000-0001-7306-5217

Murat Kose 0000-0002-7487-9287

Proje Numarası Çalışmaya ilişkin Sağlık Bakanlığı onayı 19.05.2020 tarihinde 2020-05-14T12_59_48 numaralı onay numarası ile alınmıştır. 21.05.2020 tarihinde de İstanbul Tıp Fakültesi Etik Kurulu'ndan onay alınmıştır.
Yayımlanma Tarihi 30 Aralık 2021
Kabul Tarihi 18 Kasım 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 5 Sayı: 3

Kaynak Göster

APA Çakmak, R., Telci Çaklılı, Ö., Ok, A., Mutlu, Ü., vd. (2021). COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet Ve Obezite Dergisi, 5(3), 279-284. https://doi.org/10.25048/tudod.959022
AMA Çakmak R, Telci Çaklılı Ö, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoğlu A, Şenkal N, Çatma Y, Kose M. COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Turk J Diab Obes. Aralık 2021;5(3):279-284. doi:10.25048/tudod.959022
Chicago Çakmak, Ramazan, Özge Telci Çaklılı, Ayşe Ok, Ümmü Mutlu, Göktuğ Sarıbeyliler, Vefa Seferova Nasifova, Alpay Medetalibeyoğlu, Naci Şenkal, Yunus Çatma, ve Murat Kose. “COVID-19 and Diabetes Mellitus: Are There Any Differences in Outcomes With Anti-Diabetic Drugs?”. Türkiye Diyabet Ve Obezite Dergisi 5, sy. 3 (Aralık 2021): 279-84. https://doi.org/10.25048/tudod.959022.
EndNote Çakmak R, Telci Çaklılı Ö, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoğlu A, Şenkal N, Çatma Y, Kose M (01 Aralık 2021) COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Türkiye Diyabet ve Obezite Dergisi 5 3 279–284.
IEEE R. Çakmak, “COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?”, Turk J Diab Obes, c. 5, sy. 3, ss. 279–284, 2021, doi: 10.25048/tudod.959022.
ISNAD Çakmak, Ramazan vd. “COVID-19 and Diabetes Mellitus: Are There Any Differences in Outcomes With Anti-Diabetic Drugs?”. Türkiye Diyabet ve Obezite Dergisi 5/3 (Aralık 2021), 279-284. https://doi.org/10.25048/tudod.959022.
JAMA Çakmak R, Telci Çaklılı Ö, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoğlu A, Şenkal N, Çatma Y, Kose M. COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Turk J Diab Obes. 2021;5:279–284.
MLA Çakmak, Ramazan vd. “COVID-19 and Diabetes Mellitus: Are There Any Differences in Outcomes With Anti-Diabetic Drugs?”. Türkiye Diyabet Ve Obezite Dergisi, c. 5, sy. 3, 2021, ss. 279-84, doi:10.25048/tudod.959022.
Vancouver Çakmak R, Telci Çaklılı Ö, Ok A, Mutlu Ü, Sarıbeyliler G, Seferova Nasifova V, Medetalibeyoğlu A, Şenkal N, Çatma Y, Kose M. COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?. Turk J Diab Obes. 2021;5(3):279-84.

Zonguldak Bülent Ecevit Üniversitesi Obezite ve Diyabet Uygulama ve Araştırma Merkezi’nin bilimsel yayım organıdır.

Web: https://obdm.beun.edu.tr/  Twitter: https://twitter.com/obezite_diyabet     Instagram: https://www.instagram.com/zbeuobezitediyabet/